Endocrine side effects of immune checkpoint inhibitors

Zulma Cardona; Jeffrey Alan Sosman; Sunandana Chandra; Wenyu Huang

doi:10.3389/fendo.2023.1157805

Endocrine side effects of immune checkpoint inhibitors

Zulma Cardona, Jeffrey Alan Sosman, Sunandana Chandra, Wenyu Huang^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for numerous malignancies. However, due to their association with autoimmunity, ICIs have resulted in a variety of side effects that involve multiple organs including the endocrine system. In this review article, we describe our current understanding of the autoimmune endocrinopathies as a result of the use of ICIs. We will review the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of the most commonly encountered endocrinopathies, including thyroiditis, hypophysitis, Type 1 diabetes, adrenalitis, and central diabetes insipidus.

Original language	English (US)
Article number	1157805
Journal	Frontiers in Endocrinology
Volume	14
DOIs	https://doi.org/10.3389/fendo.2023.1157805
State	Published - 2023

Keywords

adrenal insufficiency
adrenalitis
central diabetes insipidus
endocrine side effects
hypophysitis
immune checkpoint inhibitor (ICI)
thyroiditis
type1 diabetes

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fendo.2023.1157805

Cite this

@article{673d1d10aa1c47aea78c4d536f80d962,

title = "Endocrine side effects of immune checkpoint inhibitors",

abstract = "Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for numerous malignancies. However, due to their association with autoimmunity, ICIs have resulted in a variety of side effects that involve multiple organs including the endocrine system. In this review article, we describe our current understanding of the autoimmune endocrinopathies as a result of the use of ICIs. We will review the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of the most commonly encountered endocrinopathies, including thyroiditis, hypophysitis, Type 1 diabetes, adrenalitis, and central diabetes insipidus.",

keywords = "adrenal insufficiency, adrenalitis, central diabetes insipidus, endocrine side effects, hypophysitis, immune checkpoint inhibitor (ICI), thyroiditis, type1 diabetes",

author = "Zulma Cardona and Sosman, {Jeffrey Alan} and Sunandana Chandra and Wenyu Huang",

note = "Publisher Copyright: Copyright {\textcopyright} 2023 Cardona, Sosman, Chandra and Huang.",

year = "2023",

doi = "10.3389/fendo.2023.1157805",

language = "English (US)",

volume = "14",

journal = "Frontiers in Endocrinology",

issn = "1664-2392",

publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Endocrine side effects of immune checkpoint inhibitors

AU - Cardona, Zulma

AU - Sosman, Jeffrey Alan

AU - Chandra, Sunandana

AU - Huang, Wenyu

PY - 2023

Y1 - 2023

N2 - Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for numerous malignancies. However, due to their association with autoimmunity, ICIs have resulted in a variety of side effects that involve multiple organs including the endocrine system. In this review article, we describe our current understanding of the autoimmune endocrinopathies as a result of the use of ICIs. We will review the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of the most commonly encountered endocrinopathies, including thyroiditis, hypophysitis, Type 1 diabetes, adrenalitis, and central diabetes insipidus.

AB - Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for numerous malignancies. However, due to their association with autoimmunity, ICIs have resulted in a variety of side effects that involve multiple organs including the endocrine system. In this review article, we describe our current understanding of the autoimmune endocrinopathies as a result of the use of ICIs. We will review the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of the most commonly encountered endocrinopathies, including thyroiditis, hypophysitis, Type 1 diabetes, adrenalitis, and central diabetes insipidus.

KW - adrenal insufficiency

KW - adrenalitis

KW - central diabetes insipidus

KW - endocrine side effects

KW - hypophysitis

KW - immune checkpoint inhibitor (ICI)

KW - thyroiditis

KW - type1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85159945736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85159945736&partnerID=8YFLogxK

U2 - 10.3389/fendo.2023.1157805

DO - 10.3389/fendo.2023.1157805

M3 - Review article

C2 - 37251665

AN - SCOPUS:85159945736

SN - 1664-2392

VL - 14

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

M1 - 1157805

ER -

Endocrine side effects of immune checkpoint inhibitors

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this